Horizon Therapeutics Ireland Designated Activity Company

Fibrotic and interstitial lung disease

Clinical research includes idiopathic pulmonary fibrosis and lung involvement linked to diffuse cutaneous systemic sclerosis, with attention to respiratory function and disease-related decline.

  • Idiopathic pulmonary fibrosis
  • Forced vital capacity
  • Systemic sclerosis-associated lung disease

The sponsor’s portfolio reflects interest in conditions where pulmonary fibrosis and connective tissue disease overlap.

Autoimmune neurology

Research activity covers neuromyelitis optica spectrum disorder in children and adolescents, as well as myasthenia gravis associated with acetylcholine receptor antibodies or muscle-specific kinase antibodies.

  • Neuromyelitis optica spectrum disorder
  • Myasthenia gravis
  • Autoantibody-mediated disease

These studies focus on immune-mediated disorders affecting the central nervous system and neuromuscular junction.

Systemic autoimmune connective tissue disease

The sponsor funds studies in diffuse cutaneous systemic sclerosis, primary discoid lupus erythematosus, and Sjögren’s syndrome, including forms with moderate-to-severe systemic disease activity.

  • Diffuse cutaneous systemic sclerosis
  • Primary discoid lupus erythematosus
  • Sjögren’s syndrome

Clinical interests extend to both organ-based manifestations and patient-reported symptom burden in chronic autoimmune disease.

Trials address immunoglobulin G4-related disease, a systemic inflammatory condition with relapsing activity and multi-organ involvement.

  • IgG4-related disease
  • Disease flare prevention
  • Immune-mediated systemic inflammation

This area adds to the sponsor’s focus on antibody-associated autoimmune disorders and long-term control of inflammatory disease activity.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of Inebilizumab for Children and Adolescents with Neuromyelitis Optica Spectrum Disorder

    Recruiting

    2 1 1 1
    Investigated drugs:
    France The Netherlands Poland Spain Sweden
  • Phase 2 Study of Daxdilimab with Prednisone in Adults with Inadequately Controlled Dermatomyositis or Anti‑Synthetase Inflammatory Myositis

    Not recruiting

    2 1 1
    Investigated drugs:
    Czechia France Germany Italy Spain
  • Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Croatia Denmark France Germany Greece +6
  • Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Croatia Denmark France Germany Greece +6
  • Study on the Effects of Fipaxalparant in Patients with Diffuse Cutaneous Systemic Sclerosis

    Not recruiting

    2 1 1
    Investigated drugs:
    Austria France Germany Greece Italy Poland +3
  • Study on the Effectiveness of Inebilizumab for Patients with IgG4-Related Disease

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands Poland Spain